The Centers for Disease Control and Prevention report 86 million American adults have prediabetes, and of those, as many as a third will become diabetics within five years.
Beginning January 1, 2015, virtually all private insurers must cover services — with no copay — that help people with elevated blood sugar levels change their diets and increase their physical activity.
Health officials hope the change in coverage will drive down diabetes rates.
At the same time, make no mistake: Entrepreneurs “feel the commercial winds blowing,” said Omada Chief Commercial Officer Mike Payne.
Read More: http://www.marketplace.org/2015/11/27/health-care/diabetes-prevention-becomes-lucrative-growth-industry
Omada Health has revealed promising results from a study that looked at how well its digital health tools could help spur weight loss among Medicare members, a milestone for the company a couple of months after it roped in new funding to develop its health management program.
OncoMed Presents Immuno-Oncology Data for Combined Blockade of DLL4, VEGF and PD1 at the Society for Immunotherapy of Cancer Annual Meeting
Preclinical Comparison Study Shows Improved Anti-Tumor and Immune Responses for Anti-DLL4/VEGF Bispecific Plus Anti-PD1 vs. Either Alone
Silk Road Medical Announces up to $57 Million in New Funding for Novel Approach to Preventing Strokes
Via: PR Newswire
Financing to Support Commercialization of First-in-Class Products for TransCarotid Artery Revascularization (TCAR) Procedure
Via: MedCity News
A few months after Outset Medical’s huge fundraise to support the clinical roll outof its Tablo dialysis system — one of the largest medtech funding rounds this year — CEO Leslie Trigg spoke at Heath 2.0 about how the company wants to transform how we think of dialysis. Aside from adding musical functions and animation and collaborating with the likes of DaVita, it wants to give patients access to their dialysis data.
Omada Health, which just nabbed $48 million in new funding, expects to have "hundreds of thousands" of health plan enrollees using its digital health services by next year, CEO Sean Duffy says.
OncoMed Presents Immuno-Oncology Data for GITRL-Fc Candidate at the Inaugural International Cancer Immunotherapy Conference
NEW YORK and REDWOOD CITY, Calif., Sept. 16, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today presented preclinical data for the company's proprietary, wholly owned GITRL-Fc agent during the afternoon poster session of the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference.
Omada Health, which provides a digital program based on the landmark NIH diabetes prevention study, raised $48 million, bringing total funding to $77.5 million. The series C round was led by Norwest Venture Partners, and includes returning investors Andreessen Horowitz and US Venture Partners, among others. Accelerator-turned venture fund Rock Health which nurtured Omada in its first class of digital health startups, also reinvested.
OncoMed Pharmaceuticals Completes Enrollment of Phase 2 ALPINE Clinical Trial of Tarextumab in Pancreatic Cancer
Enrollment of 177 Patients Completed Over Eight Months Ahead of Schedule
REDWOOD CITY, Calif., July 28, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced dosing of the first patient in its anti-RSPO3 antibody (OMP-131R10) Phase 1a/1b clinical trial. Anti-RSPO3 is the first drug in its class to target the R-spondin-LGR pathway, an important cancer stem cell pathway identified by OncoMed researchers.